Elanco Animal Health Inc
Close on Oct 19, 2026
- Market cap
- $11.88B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | $1.37B | $0.11 | $0.34 |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | Before market open | $1.37B | $0.11 | $0.40 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | Before market open | $1.14B | $-0.56 | $0.13 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $1.14B | $-0.07 | $0.19 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $1.24B | $0.02 | $0.26 |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | Before market open | $1.19B | $0.13 | $0.37 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | Before market open | $1.02B | $-0.02 | $0.14 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $1.03B | $0.73 | $0.13 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | $1.18B | $-0.10 | $0.30 |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 26, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | 2026 Full Year | $1.01B to $1.04B | Raised |
| Adjusted EBITDAnon-GAAP | 2026 Third Quarter | $200.00M to $215.00M | New |
| Adjusted EPSnon-GAAP | 2026 Full Year | $1.10 to $1.16 | Raised |
| Adjusted Earnings per Sharenon-GAAP | 2026 Third Quarter | $0.19 to $0.22 | New |
| adjusted gross marginnon-GAAP | 2026 | 55.2% to 55.6% | Raised |
| year-end net leverage ratio targetnon-GAAP | Full Year 2026 | 3 | Lowered |
| innovation revenue targetnon-GAAP | Full Year 2026 | $1.25B | Raised |
| operating expensesnon-GAAP | third quarter | 10% growth | New |
| organic constant currency growthnon-GAAP | Full Year 2026 | 6% to 7% growth | New |
| Revenue | 2026 Full Year | $5.09B to $5.14B | Raised |
| revenue growthnon-GAAP | third quarter | 5% to 7% growth | New |
| Revenue | 2026 Third Quarter | $1.20B to $1.22B | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Elanco Animal Health filed with the SEC
Elanco Animal Health Reports Second Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
Elanco Animal Health Reports First Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
Results of operations · EX-99.1 to Form 8-K
J.P. Morgan Healthcare Conference Jeff Simmons President & CEO January 13, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Elanco Investor Day Defines New Era as Sustainable
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Elanco Animal Health Reports Third Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Elanco Animal Health Reports Second Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Elanco Appoints Robert (Bob) VanHimbergen as
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Elanco Animal Health Reports First Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Elanco Announces Changes to Board
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Elanco Animal Health Reports Fourth Quarter and Full Year 2024 Results
Results of operations · EX-99.1 to Form 8-K
President & Chief Executive Officer
Regulation FD disclosure · EX-99.1 to Form 8-K
Elanco Strengthens Board of Directors with Addition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Elanco Animal Health Reports Third Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
Elanco Animal Health Reports Second Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
Elanco Completes Sale of Aqua Business
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Elanco Animal Health Reports First Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Elanco Animal Health Reports Fourth Quarter and Full Year 2023 Results
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Elanco Announces Sale of Aqua Business for
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
President & Chief Executive Officer
Regulation FD disclosure · EX-99.1 to Form 8-K
Elanco Animal Health Announces Planned Board
Regulation FD disclosure · EX-99.1 to Form 8-K
Elanco Animal Health Reports Third Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
Elanco Announces Corporate Governance Enhancements
Regulation FD disclosure · EX-99.1 to Form 8-K
Elanco Animal Health Reports Second Quarter
Material agreement · Results of operations · New financial obligation · EX-99.1 to Form 8-K
Protection Agency (EPA) Completes Review of Seresto ® Collar and Confirms Continued Registration; Data Affirms Safety Profile
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
On July 13, 2023, Elanco Animal Health Incorporated and the
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Elanco Animal Health Reports First Quarter 2023
Results of operations · EX-99.1 to Form 8-K
The financial tables in this Exhibit 99.1 reflect the revisions
Results of operations · EX-99.1 to Form 8-K/A
Fourth Quarter and Full Year 2022 Results
Results of operations · EX-99.1 to Form 8-K
President & Chief Executive Officer
Regulation FD disclosure · EX-99.1 to Form 8-K
Elanco Animal Health Reports Third Quarter 2022
Results of operations · EX-99.1 to Form 8-K
Changes to its Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Elanco Animal Health Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
and Ginkgo Bioworks Launch BiomEdit, a New
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Elanco Animal Health Incorporated Announces
Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Elanco Animal Health Incorporated Announces
Regulation FD disclosure · EX-99.1 to Form 8-K
Elanco Animal Health Reports Fourth Quarter
Results of operations · Charter or bylaw amendment · EX-99.1 to Form 8-K
January 11, 2022 J.P. Morgan Healthcare Conference Jeff Simmons President & Chief Executive Officer
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K